Fresh from hauling in GSK’s budget-priced gene therapy group, Orchard harvests $150M mega-round. Is it time to IPO?
Just a few months ago Orchard Therapeutics was handed the opportunity of taking over GlaxoSmithKline’s gene therapy group, which had pushed the field’s second product, Strimvelis, to the European market — without seeing much in the way of a return.
This morning, Orchard is back in the news, adding $150 million to the reported $140 million it had already raised to get to this stage. And that may well include an IPO in the near future.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.